Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

A specific RAD51 haplotype increases breast cancer risk in Jewish non-Ashkenazi high-risk women.

Gal I, Kimmel G, Gershoni-Baruch R, Papa MZ, Dagan E, Shamir R, Friedman E.

Eur J Cancer. 2006 May;42(8):1129-34. Epub 2006 Apr 18.

PMID:
16624550
2.

A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers.

Levy-Lahad E, Lahad A, Eisenberg S, Dagan E, Paperna T, Kasinetz L, Catane R, Kaufman B, Beller U, Renbaum P, Gershoni-Baruch R.

Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3232-6.

3.

The 1100delAT BRCA1 and the 8765delAG BRCA2 mutations: occurrence in high-risk non-Ashkenazi Jews and haplotype comparison of Jewish and non-Jewish carriers.

Gal I, Gershoni Baruch R, Haber D, Dagan E, Eisenberg-Barzilai S, Zidan J, Friedman E.

Fam Cancer. 2004;3(1):11-4.

PMID:
15131400
4.

Genetic variation in IGF-1 and breast cancer risk in Ashkenazi carriers and noncarriers of BRCA1/2 mutations.

Khoury-Shakour S, Lejbkowicz F, Barnett-Griness O, Tamir A, Pinchev M, Rennert G.

Eur J Cancer Prev. 2009 Sep;18(5):361-7. doi: 10.1097/CEJ.0b013e32832e0942.

PMID:
19543094
5.

A single nucleotide polymorphism in the 5' untranslated region of RAD51 and risk of cancer among BRCA1/2 mutation carriers.

Wang WW, Spurdle AB, Kolachana P, Bove B, Modan B, Ebbers SM, Suthers G, Tucker MA, Kaufman DJ, Doody MM, Tarone RE, Daly M, Levavi H, Pierce H, Chetrit A, Yechezkel GH, Chenevix-Trench G, Offit K, Godwin AK, Struewing JP.

Cancer Epidemiol Biomarkers Prev. 2001 Sep;10(9):955-60.

6.

Analysis of BRCA1/BRCA2 genes' contribution to breast cancer susceptibility in high risk Jewish Ashkenazi women.

Distelman-Menachem T, Shapira T, Laitman Y, Kaufman B, Barak F, Tavtigian S, Friedman E.

Fam Cancer. 2009;8(2):127-33. doi: 10.1007/s10689-008-9216-6. Epub 2008 Sep 17.

PMID:
18798010
7.

Hormone replacement therapy is more prevalent among Jewish BRCA1/2 mutation carriers.

Sade RB, Chetrit A, Figer A, Papa MZ, Flex D, Rizel S, Friedman E.

Eur J Cancer. 2006 Mar;42(5):650-5. Epub 2006 Feb 7.

PMID:
16464572
8.

The Tyr978X BRCA1 mutation: occurrence in non-Jewish Iranians and haplotype in French-Canadian and non-Ashkenazi Jews.

Quintana-Murci L, Gal I, Bakhan T, Quach H, Sayar SH, Shiri-Sverdlov R, Baruch RG, McElreavey K, Dagan E, Narod S, Friedman E.

Fam Cancer. 2005;4(2):85-8.

PMID:
15951957
9.

BRCA1 breast cancer risk is modified by CYP19 polymorphisms in Ashkenazi Jews.

Raskin L, Lejbkowicz F, Barnett-Griness O, Dishon S, Almog R, Rennert G.

Cancer Epidemiol Biomarkers Prev. 2009 May;18(5):1617-23. doi: 10.1158/1055-9965.EPI-09-0060. Epub 2009 Apr 14.

10.

A single-nucleotide polymorphism in the RAD51 gene modifies breast cancer risk in BRCA2 carriers, but not in BRCA1 carriers or noncarriers.

Kadouri L, Kote-Jarai Z, Hubert A, Durocher F, Abeliovich D, Glaser B, Hamburger T, Eeles RA, Peretz T.

Br J Cancer. 2004 May 17;90(10):2002-5.

11.

Insulin-like growth factor I polymorphism and breast cancer risk in Jewish women.

Figer A, Karasik YP, Baruch RG, Chetrit A, Papa MZ, Sade RB, Rizel S, Friedman E.

Isr Med Assoc J. 2002 Oct;4(10):759-62. Erratum in: Isr Med Assoc J. 2003 May;5(5):389. Riezel Shulamith [corrected to Rizel Shulamith].

PMID:
12389335
12.

The RAD51 135 G>C polymorphism modifies breast cancer and ovarian cancer risk in Polish BRCA1 mutation carriers.

Jakubowska A, Gronwald J, Menkiszak J, Górski B, Huzarski T, Byrski T, Edler L, Lubiñski J, Scott RJ, Hamann U.

Cancer Epidemiol Biomarkers Prev. 2007 Feb;16(2):270-5.

13.

Could the 185delAG BRCA1 mutation be an ancient Jewish mutation?

Bar-Sade RB, Theodor L, Gak E, Kruglikova A, Hirsch-Yechezkel G, Modan B, Kuperstein G, Seligsohn U, Rechavi G, Friedman E.

Eur J Hum Genet. 1997 Nov-Dec;5(6):413-6.

PMID:
9450187
14.

High incidence of BRCA1-2 germline mutations, previous breast cancer and familial cancer history in Jewish patients with uterine serous papillary carcinoma.

Biron-Shental T, Drucker L, Altaras M, Bernheim J, Fishman A.

Eur J Surg Oncol. 2006 Dec;32(10):1097-100. Epub 2006 May 2.

PMID:
16650962
15.

RAD51 135G>C does not modify breast cancer risk in non-BRCA1/2 mutation carriers: evidence from a meta-analysis of 12 studies.

Yu KD, Yang C, Fan L, Chen AX, Shao ZM.

Breast Cancer Res Treat. 2011 Apr;126(2):365-71. doi: 10.1007/s10549-010-0937-5. Epub 2010 May 12.

PMID:
20461453
16.

Genetic variants of BLM interact with RAD51 to increase breast cancer susceptibility.

Ding SL, Yu JC, Chen ST, Hsu GC, Kuo SJ, Lin YH, Wu PE, Shen CY.

Carcinogenesis. 2009 Jan;30(1):43-9. doi: 10.1093/carcin/bgn233. Epub 2008 Oct 28.

PMID:
18974064
17.

Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.

Lose F, Duffy DL, Kay GF, Kedda MA, Spurdle AB; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer; Australian Ovarian Cancer Study Management Group.

J Natl Cancer Inst. 2008 Nov 5;100(21):1519-29. doi: 10.1093/jnci/djn345. Epub 2008 Oct 28.

PMID:
18957670
18.

Concomitant BRCA1 and BRCA2 gene mutations in an Ashkenazi Jewish woman with primary breast and ovarian cancer.

Spannuth WA, Thaker PH, Sood AK.

Am J Obstet Gynecol. 2007 Apr;196(4):e6-9.

PMID:
17403394
19.

RAD51 135G>C polymorphism and breast cancer risk: a meta-analysis.

Zhou GW, Hu J, Peng XD, Li Q.

Breast Cancer Res Treat. 2011 Jan;125(2):529-35. doi: 10.1007/s10549-010-1031-8. Epub 2010 Jul 11.

PMID:
20623332
20.

BRCA1 and BRCA2 germline mutation analysis among Indian women from south India: identification of four novel mutations and high-frequency occurrence of 185delAG mutation.

Vaidyanathan K, Lakhotia S, Ravishankar HM, Tabassum U, Mukherjee G, Somasundaram K.

J Biosci. 2009 Sep;34(3):415-22.

Supplemental Content

Support Center